Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2329–2352 of 33,158 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: PLACEBO Clear all

Conditions: Glabellar Rhytides, Frown Lines Between the Eyebrows
Interventions: Mentor Purified Toxin Botulinum Toxin Type A, Preservative-free Saline; Drug
Lead sponsor: Mentor Worldwide, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 699 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Santa Barbara, California

Conditions: Parkinson's Disease
Interventions: PYM50028, Placebo; Drug
Lead sponsor: Phytopharm; Industry
Eligibility: 35 Years to 75 Years
Enrollment: 425 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 41
States / cities: Scottsdale, Arizona • Irvine, California • La Jolla, California + 37 more

Conditions: Metabolism and Nutrition Disorder, Obesity
Interventions: NNC0174-0833, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 22 Years to 55 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Glycemic Response, Menopause Symptoms
Interventions: Reducose® (Mulberry leaf extract), Placebo; Dietary Supplement
Lead sponsor: Phynova Group Ltd; Industry
Eligibility: 40 Years to 60 Years · Female only
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Stroke, Acute Ischemic Stroke
Interventions: Repinotan HCl (BAYX3702), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 782 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 28
States / cities: Los Angeles, California • Oceanside, California • San Diego, California + 25 more

Conditions: Obesity
Interventions: Semaglutide, Tirzepatide, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Multi Organ Failure, Exocrine Pancreatic Insufficiency
Interventions: RELiZORB™, Placebo; Device · Other
Lead sponsor: Inova Health Care Services; Other
Eligibility: 18 Years to 89 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Falls Church, Virginia

Conditions: Opioid Use Disorder, Cannabis Use
Interventions: Cannabis, Placebo Cannabis, Intranasal Opioid Agonist, Oral Opioid Agonist; Drug
Lead sponsor: Shanna Babalonis, PhD; Other
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency, Carnitine Palmitoyltransferase Deficiency 2, Very Long Chain Acyl Coa Dehydrogenase Deficiency, Trifunctional Protein Deficiency
Interventions: Nutritional Ketone Supplement, Isocaloric Placebo Supplement; Dietary Supplement
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Seasonal Allergic Rhinitis, Hay Fever
Interventions: Beclomethasone dipropionate, Placebo Nasal Aerosol; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 4
States / cities: Austin, Texas • New Braunfels, Texas • San Antonio, Texas + 1 more

Conditions: Postoperative Pain After Uterine Fibroid Embolization, Uterine Fibroids (UF), Uterine Fibroids, Pelvic Pain, Pain Management
Interventions: TUNES (Transmucosal Uterosacral Electrical Stimulation), Sham TUNES Device; Device
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 28 Years to 52 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Cocaine Use Disorder
Interventions: Phendimetrazine, Cocaine, Placebo; Drug
Lead sponsor: William Stoops; Other
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Schizophrenia
Interventions: Oxytocin; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Catonsville, Maryland

Conditions: Chronic Pain, Opioid Use Disorder
Interventions: 400 mg Cannabidiol, 800 mg Cannabidiol, 1200 mg Cannabidiol, Beta carotene oral solution without CBD; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Opioid Use Disorder, Opioid Abuse and Addiction, Narcotic-Related Disorders, Substance-Related Disorders, Chemically-Induced Disorders, Mental Disorder, Opioid
Interventions: Semaglutide Pen Injector, Placebo; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 4
States / cities: Baltimore, Maryland • Fall River, Massachusetts • New York, New York + 1 more

Conditions: Diabetes Mellitus, Type 2
Interventions: CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 10 Years to 18 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 21
States / cities: New Haven, Connecticut • Boynton Beach, Florida • Jacksonville, Florida + 18 more

Conditions: Clostridium Infections, Methicillin-resistant Staphylococcus Aureus (MRSA), Vancomycin-Resistant Enterococci, Carbapenem-Resistant Enterobacteriaceae, Asymptomatic Infections
Interventions: Resistant Potato Starch, Maltodextrin; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Volunteers
Interventions: PF-04308515, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Medication-related Osteonecrosis of the Jaw, Bisphosphonate-related Osteonecrosis of the Jaw, Avascular Necrosis
Interventions: Pentoxifylline, Placebo, Tocopherol; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 90 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 4
States / cities: Birmingham, Alabama • Ann Arbor, Michigan • Lake Success, New York + 1 more

Conditions: Progressive Pulmonary Fibrosis, Interstitial Lung Disease
Interventions: Treprostinil Palmitil Inhalation Powder, Placebo; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: DuBois, Pennsylvania

Conditions: Hypoglycemia, Diabetes Mellitus, Type 1
Interventions: Dasiglucagon, GlucaGen, Placebo; Drug
Lead sponsor: Zealand Pharma; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Chemotherapy-Induced Nausea and Vomiting
Interventions: Palonosetron, Ondansetron, Placebo to Ondansetron, Placebo to Palonosetron; Drug
Lead sponsor: Helsinn Healthcare SA; Industry
Eligibility: Up to 16 Years
Enrollment: 502 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 14
States / cities: Little Rock, Arkansas • Duarte, California • Aurora, Colorado + 11 more

Conditions: Pain, Postoperative, Bunion
Interventions: COV155, placebo; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years and older
Enrollment: 406 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 5
States / cities: Anaheim, California • Pasadena, California • Pasadena, Maryland + 2 more

Conditions: Dengue
Interventions: rDEN2Δ30-7169 vaccine, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Safety and Efficacy Study of Repeat Treatment With PurTox® Botulinum Toxin Type A for Frown Lines Between the Eyebrows

Investigation of Cogane (PYM50028) in Early-stage Parkinson's Disease (CONFIDENT-PD)

Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Subjects With Obesity or Overweight

Impact of Reducose® on Glycemic Response and Menopausal Symptoms in Perimenopausal Women (CALM-R)

Repinotan in Patients With Acute Ischemic Stroke

Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions

Evaluating the Utility of RELiZORB™ for Treating Feeding Intolerance in Critically Ill Adults With Multi-Organ Failure

Cannabis Effects on Opioid Self-Administration

Oral Ketones and Exercise Among Patients With Long-chain Fatty Acid Oxidation Disorders

Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)

Transmucosal Uterosacral Electrical Stimulation for Pelvic Pain Relief

Reinforcing Effects of Cocaine During Phendimetrazine Maintenance

Brain Blood Flow Changes Elicited by Oxytocin in Volunteers With and Without Schizophrenia

Cannabidiol in Opioid Use Disorder and Chronic Pain

GLP-1R Agonist Treatment for Opioid Use Disorder

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes

A Clinical Trial of Resistant Potato Starch for Gut MDRO Decolonization

A Phase 1 Single-Dose Escalation Study of PF-04308515 in Healthy Volunteers

Pentoxifylline and Tocopherol (PENTO) in the Treatment of Medication-related Osteonecrosis of the Jaw (MRONJ)

A Study to Assess the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Progressive Pulmonary Fibrosis (PPF)

A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects

Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients

Safety and Efficacy Study of COV155 for Post-operative Bunionectomy Pain

Evaluating the Safety and Immune Response to a Dengue Virus Vaccine in Healthy Adults